Drug Trial Radar · NCT00560209
Study of ONO-1101 in Patients Scheduled for Coronary Angiography
Last checked: Nov 21, 2026Latest source record: Jun 13, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
183
Actual
Start
Nov 2007
Primary completion
Nov 2008
Sponsor
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 19, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of ONO-1101 in patients scheduled for coronary angiography, in a double-blind, randomized, placebo-controlled, parallel group, multi-center study.
Conditions
- Coronary Artery Disease
Interventions
ONO-1101Drug
placebo for 1 minute IV
ONO-1101Drug
0.06 mg/kg for 1 minute IV
ONO-1101Drug
0.125 mg/kg for 1 minute IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- CT image qualityTime frame: one day
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kinki Region
Kinki, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.